Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis
- 28 April 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (5), 527-537
- https://doi.org/10.1111/j.1365-2125.2006.02667.x
Abstract
To describe the pharmacokinetic-pharmacodynamic (PK-PD) characteristics of the direct thrombin inhibitor dabigatran in hip replacement patients by assessing coagulation parameters activated partial thromboplastin time (aPTT) and ecarin clotting time (ECT), interindividual variability and factors affecting PD responses. BISTRO I patients received oral dabigatran etexilate postsurgery for 6-10 days. Dabigatran plasma concentrations and aPTT/ECT were measured on the day of surgery, on subsequent days and at steady state. PK-PD characteristics of the dabigatran-aPTT/ECT relationships were evaluated using NONMEM V. The dabigatran concentration-aPTT relationship was described combining a linear and an E(max) model. Mean baseline aPTT was 33.4 s and E(max) (maximum increase in aPTT contributed by the E(max) model) was 26.9 s. The dabigatran concentration needed to attain 50% of maximum effect (EC(50)) was 94.7 ng ml(-1) and the mean slope of the linear concentration-response relationship (SLOP) was 0.0509 s ng(-1) ml(-1). Baseline aPTT and E(max) were highest following surgery and declined with time. The dabigatran concentration-ECT relationship fitted a linear model. Mean baseline ECT was 28 s and decreased with time; 50% of the maximum effect was observed after 2.9 days. SLOP decreased from 0.38 to 0.27 s ng(-1) ml(-1) with a half-life of 1.1 day, indicating greater PD effects on the day of surgery. Interindividual and residual variability was low. Covariates could not explain variability of this model. aPTT and ECT prolongation were directly correlated with dabigatran concentrations. Blood coagulation prolongation was most pronounced following surgery. Data suggest that ECT provides a more precise description of the anticoagulant effect than aPTT.This publication has 24 references indexed in Scilit:
- Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in HumansThe Journal of Clinical Pharmacology, 2005
- Understanding the dynamics of thrombin in cardiovascular disease: Pathobiology and biochemistry for the clinicianAmerican Heart Journal, 2005
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004
- Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral XimelagatranClinical Pharmacokinetics, 2003
- Serine proteases as targets for antithrombotic therapyDrugs of the Future, 2003
- Monitoring of Anticoagulant Effects of Direct Thrombin InhibitorsSeminars in Thrombosis and Hemostasis, 2002
- Laboratory Assessment of Antithrombotic Therapy: What Tests and If So Why?Pathophysiology of Haemostasis and Thrombosis, 1997
- 1- and 7-year risk of cardiac events in relation to Holter monitoring in patients admitted with chest pain in whom AMI is not confirmedInternational Journal of Angiology, 1995
- Initial experience withhirudin andstreptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 trialThe American Journal of Cardiology, 1995
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992